Search Results - "Pabst, K.M."

1497P Safety and efficacy of [90Y]Y-FAPI-46 radioligand therapy in patients with advanced sarcomas and other cancer entities by Hamacher, R.W., Pabst, K.M., Kessler, L., Costa, P.F., Ferdinandus, J., Weber, M., Lippert, M., Lueckerath, K., Hirmas, N., Kostbade, K., Mavroeidi, I.A., Schuler, M.H.H., Ahrens, M., Rischpler, C., Bauer, S., Herrmann, K., Siveke, J.T., Fendler, W.P.

Get full text

1392P Lutetium-177-prostate-specific membrane antigen therapy (177Lu-PSMA) in patients (Pts) with prior radium-223 (223Ra): Safety and effectiveness outcomes by Rahbar, K., Essler, M., Eiber, M., la Fougère, C., Prasad, V., Fendler, W.P., Rassek, P., Hasa, E., Dittmann, H., Bundschuh, R.A., Pabst, K.M., Kurtinecz, M., Schmall, A., Verholen, F., Sartor, O.

Get full text

99P Fibroblast activation protein alpha (FAP) as theranostic target in solitary fibrous tumor by Hamacher, R.W., Pabst, K.M., Cheung, P.F., Heilig, C.E., Hüllein, J., Liffers, S-T., Schaarschmidt, B.M., Costa, P., Kessler, L., Falkenhorst, J., Glimm, H., Umutlu, L., Schuler, M.H.H., Hübschmann, D., Bauer, S., Fröhling, S., Herrmann, K., Siveke, J., Schildhaus, H-U., Fendler, W.

Get full text